Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

209 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Venetoclax therapy in chronic lymphocytic leukaemia patients relapsed after allogeneic haematopoietic stem cell transplantation.
Perutelli F, Boccellato E, Montalbano MC, Catania G, Deodato M, Frustaci AM, Innocenti I, Moia R, Quaglia FM, Quaresmini G, Rivela P, Gaidano G, Krampera M, Laurenti L, Rambaldi A, Bruno B, Vitale C, Coscia M. Perutelli F, et al. Among authors: krampera m. Br J Haematol. 2025 Jan 7. doi: 10.1111/bjh.19976. Online ahead of print. Br J Haematol. 2025. PMID: 39777647
CAT rs1001179 Single Nucleotide Polymorphism Identifies an Aggressive Clinical Behavior in Chronic Lymphocytic Leukemia.
Galasso M, Salaorni V, Moia R, Mozzo V, Lovato E, Cosentino C, Perbellini O, Gambino S, Lovato O, Carazzolo ME, Ferrarini I, Quaglia FM, Donadelli M, Romanelli MG, Visco C, Krampera M, Gaidano G, Scupoli MT. Galasso M, et al. Among authors: krampera m. Hematol Oncol. 2024 Nov;42(6):e70002. doi: 10.1002/hon.70002. Hematol Oncol. 2024. PMID: 39540258 Free PMC article.
Brexucabtagene autoleucel in-vivo expansion and BTKi refractoriness have a negative influence on progression-free survival in mantle cell lymphoma: Results from CART-SIE study.
Stella F, Chiappella A, Magni M, Bonifazi F, De Philippis C, Musso M, Cutini I, Ljevar S, Barbui AM, Farina M, Martino M, Massaia M, Grillo G, Angelillo P, Botto B, Patriarca F, Krampera M, Arcaini L, Tisi MC, Zinzani P, Sorà F, Bramanti S, Pennisi M, Carniti C, Corradini P. Stella F, et al. Among authors: krampera m. Br J Haematol. 2024 Dec 22. doi: 10.1111/bjh.19961. Online ahead of print. Br J Haematol. 2024. PMID: 39710966
B-cell receptor signaling activity identifies patients with mantle cell lymphoma at higher risk of progression.
Gambino S, Quaglia FM, Galasso M, Cavallini C, Chignola R, Lovato O, Giacobazzi L, Caligola S, Adamo A, Putta S, Aparo A, Ferrarini I, Ugel S, Giugno R, Donadelli M, Dando I, Krampera M, Visco C, Scupoli MT. Gambino S, et al. Among authors: krampera m. Sci Rep. 2024 Mar 19;14(1):6595. doi: 10.1038/s41598-024-55728-9. Sci Rep. 2024. PMID: 38503806 Free PMC article.
A real-life study of daratumumab-bortezomib-dexamethasone (D-VD) in lenalidomide exposed/refractory multiple myeloma patients: a report from the Triveneto Myeloma Working Group.
Barilà G, Quaglia FM, Furlan A, Pescosta N, Bonalumi A, Marcon C, Pascarella A, Tinelli M, De March E, Lico A, Sartori R, Clissa C, De Sabbata G, Nappi D, Porrazzo M, De Marchi R, Pavan L, Tosetto A, Gherlinzoni F, Krampera M, Bassan R, Patriarca F, Semenzato G, Zambello R. Barilà G, et al. Among authors: krampera m. Ann Hematol. 2024 Jan;103(1):125-132. doi: 10.1007/s00277-023-05443-8. Epub 2023 Sep 20. Ann Hematol. 2024. PMID: 37731147 Free PMC article.
Long-term remissions with Gilteritinib in early relapse after allogeneic stem cell transplantation of FLT3/NPM1 mutated acute myeloid leukemia.
Tamellini E, Sorio M, Andreini A, Tecchio C, Nadali G, Bernardelli A, Ferrarini I, Crosera L, Vatteroni A, Simio C, Benedetti F, Krampera M, Tanasi I. Tamellini E, et al. Among authors: krampera m. Blood Cell Ther. 2024 Jun 14;7(3):75-78. doi: 10.31547/bct-2024-005. eCollection 2024 Aug 25. Blood Cell Ther. 2024. PMID: 39263622 Free PMC article.
Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy.
Palandri F, Palumbo GA, Benevolo G, Iurlo A, Elli EM, Abruzzese E, Polverelli N, Tiribelli M, Auteri G, Tieghi A, Caocci G, Binotto G, Cavazzini F, Branzanti F, Beggiato E, Miglino M, Bosi C, Crugnola M, Bocchia M, Martino B, Pugliese N, Scaffidi L, Venturi M, Duminuco A, Isidori A, Cattaneo D, Krampera M, Pane F, Cilloni D, Semenzato G, Lemoli RM, Cuneo A, Trawinska MM, Vianelli N, Cavo M, Bonifacio M, Breccia M. Palandri F, et al. Among authors: krampera m. Cancer. 2024 Apr 15;130(8):1270-1280. doi: 10.1002/cncr.35156. Epub 2023 Dec 28. Cancer. 2024. PMID: 38153814 Free article.
Long-term survival can be achieved in a significant fraction of older patients with core binding factor acute myeloid leukemia treated with intensive chemotherapy.
Mosna F, Borlenghi E, Litzow M, Byrd JC, Papayannidis C, Tecchio C, Ferrara F, Marcucci G, Cairoli R, Morgan EA, Gurrieri C, Yeung CCS, Deeg HJ, Capelli D, Candoni A, Gotlib JR, Lunghi M, Pullarkat S, Lanza F, Galimberti S, Forghieri F, Venditti A, Festuccia M, Audisio E, Marvalle D, Rigolin GM, Roti G, DiBona E, Visani G, Albano F, Eisfeld AK, Valent P, Huls G, Borthakur G, Krampera M, Martinelli G, Kröger N, Sperotto A, Gottardi M. Mosna F, et al. Among authors: krampera m. Haematologica. 2024 Oct 10. doi: 10.3324/haematol.2024.285448. Online ahead of print. Haematologica. 2024. PMID: 39385741 Free article.
Out of specification Tisagenlecleucel is associated with outcomes comparable to standard of care product in relapsed or refractory diffuse large B-cell lymphoma.
De Philippis C, Zucchinetti C, Mannina D, Krampera M, Zinzani PL, Chiappella A, di Rocco A, Orcioulo E, Tisi MC, Pistolese F, Giordano L, Santoro A, Bramanti S. De Philippis C, et al. Among authors: krampera m. Bone Marrow Transplant. 2024 Apr;59(4):569-571. doi: 10.1038/s41409-024-02205-6. Epub 2024 Jan 25. Bone Marrow Transplant. 2024. PMID: 38272998 No abstract available.
Efficacy of Midostaurin Combined With Intensive Chemotherapy in Core Binding Factor Leukemia: A Phase II Clinical Trial.
Cairoli R, Gatti A, Grillo G, Stefanucci MR, Di Camillo B, Fumagalli M, Krampera M, Nadali G, Zappasodi P, Borlenghi E, Todisco E, Ubezio M, Bernardi M, Molteni A, Basilico C, Turrini M, Greco R, Mancini V, Riva M, Bernasconi DP, Brando B, Veronese SM, Beghini A. Cairoli R, et al. Among authors: krampera m. Am J Hematol. 2025 Feb;100(2):346-349. doi: 10.1002/ajh.27547. Epub 2024 Dec 10. Am J Hematol. 2025. PMID: 39659145 Clinical Trial.
209 results